No studies have investigated the role of contralateral prophylactic mastectomy in the risk reduction of contralateral breast cancer in patients with a diagnosis of breast cancer that harbor a genetic mutation in non-BRCA1/2 genes (CHEK2, TP53, ATM, PALB2, CDH1 and PTEN). This evidence concerns the gene PALB2 and breast cancer.